409 related articles for article (PubMed ID: 21514219)
1. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
Zhang B; Beeghly-Fadiel A; Long J; Zheng W
Lancet Oncol; 2011 May; 12(5):477-88. PubMed ID: 21514219
[TBL] [Abstract][Full Text] [Related]
2. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
[TBL] [Abstract][Full Text] [Related]
3. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
4. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk.
Baynes C; Healey CS; Pooley KA; Scollen S; Luben RN; Thompson DJ; Pharoah PD; Easton DF; Ponder BA; Dunning AM;
Breast Cancer Res; 2007; 9(2):R27. PubMed ID: 17428325
[TBL] [Abstract][Full Text] [Related]
5. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.
Johnson N; Fletcher O; Palles C; Rudd M; Webb E; Sellick G; dos Santos Silva I; McCormack V; Gibson L; Fraser A; Leonard A; Gilham C; Tavtigian SV; Ashworth A; Houlston R; Peto J
Hum Mol Genet; 2007 May; 16(9):1051-7. PubMed ID: 17341484
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
Einarsdóttir K; Rosenberg LU; Humphreys K; Bonnard C; Palmgren J; Li Y; Li Y; Chia KS; Liu ET; Hall P; Liu J; Wedrén S
Breast Cancer Res; 2006; 8(6):R67. PubMed ID: 17132159
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review.
Zhang X; Zhang L; Tian C; Yang L; Wang Z
BJOG; 2014 May; 121(6):664-74. PubMed ID: 24548744
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants associated with breast-cancer risk.
Narod SA
Lancet Oncol; 2011 May; 12(5):415-6. PubMed ID: 21514220
[No Abstract] [Full Text] [Related]
9. Genetic predisposition to breast cancer: past, present, and future.
Turnbull C; Rahman N
Annu Rev Genomics Hum Genet; 2008; 9():321-45. PubMed ID: 18544032
[TBL] [Abstract][Full Text] [Related]
10. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Southey MC; Goldgar DE; Winqvist R; Pylkäs K; Couch F; Tischkowitz M; Foulkes WD; Dennis J; Michailidou K; van Rensburg EJ; Heikkinen T; Nevanlinna H; Hopper JL; Dörk T; Claes KB; Reis-Filho J; Teo ZL; Radice P; Catucci I; Peterlongo P; Tsimiklis H; Odefrey FA; Dowty JG; Schmidt MK; Broeks A; Hogervorst FB; Verhoef S; Carpenter J; Clarke C; Scott RJ; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Peto J; Dos-Santos-Silva I; Fletcher O; Johnson N; Bolla MK; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Burwinkel B; Yang R; Guénel P; Truong T; Menegaux F; Sanchez M; Bojesen S; Nielsen SF; Flyger H; Benitez J; Zamora MP; Perez JI; Menéndez P; Anton-Culver H; Neuhausen S; Ziogas A; Clarke CA; Brenner H; Arndt V; Stegmaier C; Brauch H; Brüning T; Ko YD; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Antonenkova NN; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Spurdle AB; Investigators K; ; Wauters E; Smeets D; Beuselinck B; Floris G; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Olson JE; Vachon C; Pankratz VS; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Kristensen V; Alnæs GG; Zheng W; Hunter DJ; Lindstrom S; Hankinson SE; Kraft P; Andrulis I; Knight JA; Glendon G; Mulligan AM; Jukkola-Vuorinen A; Grip M; Kauppila S; Devilee P; Tollenaar RA; Seynaeve C; Hollestelle A; Garcia-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson M; Eccles DM; Rafiq S; Tapper WJ; Gerty SM; Hooning MJ; Martens JW; Collée JM; Tilanus-Linthorst M; Hall P; Li J; Brand JS; Humphreys K; Cox A; Reed MW; Luccarini C; Baynes C; Dunning AM; Hamann U; Torres D; Ulmer HU; Rüdiger T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Swerdlow A; Ashworth A; Orr N; Jones M; González-Neira A; Pita G; Alonso MR; Álvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; Simard J; Dumont M; Soucy P; Eeles R; Muir K; Wiklund F; Gronberg H; Schleutker J; Nordestgaard BG; Weischer M; Travis RC; Neal D; Donovan JL; Hamdy FC; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Schaid DJ; Kelley JL; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Butterbach K; Park J; Kaneva R; Batra J; Teixeira MR; Kote-Jarai Z; Olama AA; Benlloch S; Renner SP; Hartmann A; Hein A; Ruebner M; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambretchs S; Doherty JA; Rossing MA; Nickels S; Eilber U; Wang-Gohrke S; Odunsi K; Sucheston-Campbell LE; Friel G; Lurie G; Killeen JL; Wilkens LR; Goodman MT; Runnebaum I; Hillemanns PA; Pelttari LM; Butzow R; Modugno F; Edwards RP; Ness RB; Moysich KB; du Bois A; Heitz F; Harter P; Kommoss S; Karlan BY; Walsh C; Lester J; Jensen A; Kjaer SK; Høgdall E; Peissel B; Bonanni B; Bernard L; Goode EL; Fridley BL; Vierkant RA; Cunningham JM; Larson MC; Fogarty ZC; Kalli KR; Liang D; Lu KH; Hildebrandt MA; Wu X; Levine DA; Dao F; Bisogna M; Berchuck A; Iversen ES; Marks JR; Akushevich L; Cramer DW; Schildkraut J; Terry KL; Poole EM; Stampfer M; Tworoger SS; Bandera EV; Orlow I; Olson SH; Bjorge L; Salvesen HB; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Pejovic T; Bean Y; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Górski B; Gronwald J; Menkiszak J; Høgdall CK; Lundvall L; Nedergaard L; Engelholm SA; Dicks E; Tyrer J; Campbell I; McNeish I; Paul J; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Cai H; Shu XO; Teten RT; Sutphen R; McLaughlin JR; Narod SA; Phelan CM; Monteiro AN; Fenstermacher D; Lin HY; Permuth JB; Sellers TA; Chen YA; Tsai YY; Chen Z; Gentry-Maharaj A; Gayther SA; Ramus SJ; Menon U; Wu AH; Pearce CL; Van Den Berg D; Pike MC; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Song H; Winship I; Chenevix-Trench G; Giles GG; Tavtigian SV; Easton DF; Milne RL
J Med Genet; 2016 Dec; 53(12):800-811. PubMed ID: 27595995
[TBL] [Abstract][Full Text] [Related]
11. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.
Ma X; Zhang B; Zheng W
Gut; 2014 Feb; 63(2):326-36. PubMed ID: 23946381
[TBL] [Abstract][Full Text] [Related]
13. Association between polymorphisms of the ataxia telangiectasia mutated gene and breast cancer risk: evidence from the current studies.
Lu PH; Wei MX; Si SP; Liu X; Shen W; Tao GQ; Chen MB
Breast Cancer Res Treat; 2011 Feb; 126(1):141-8. PubMed ID: 20665102
[TBL] [Abstract][Full Text] [Related]
14. The genetic epidemiology of breast cancer genes.
Thompson D; Easton D
J Mammary Gland Biol Neoplasia; 2004 Jul; 9(3):221-36. PubMed ID: 15557796
[TBL] [Abstract][Full Text] [Related]
15. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.
Tavtigian SV; Oefner PJ; Babikyan D; Hartmann A; Healey S; Le Calvez-Kelm F; Lesueur F; Byrnes GB; Chuang SC; Forey N; Feuchtinger C; Gioia L; Hall J; Hashibe M; Herte B; McKay-Chopin S; Thomas A; Vallée MP; Voegele C; Webb PM; Whiteman DC; ; ; ; Sangrajrang S; Hopper JL; Southey MC; Andrulis IL; John EM; Chenevix-Trench G
Am J Hum Genet; 2009 Oct; 85(4):427-46. PubMed ID: 19781682
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
17. Association between ATM 5557G>A polymorphism and breast cancer risk: a meta-analysis.
Mao C; Chung VC; He BF; Luo RC; Tang JL
Mol Biol Rep; 2012 Feb; 39(2):1113-8. PubMed ID: 21603857
[TBL] [Abstract][Full Text] [Related]
18. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry.
Bernstein JL; Teraoka S; Southey MC; Jenkins MA; Andrulis IL; Knight JA; John EM; Lapinski R; Wolitzer AL; Whittemore AS; West D; Seminara D; Olson ER; Spurdle AB; Chenevix-Trench G; Giles GG; Hopper JL; Concannon P
Hum Mutat; 2006 Nov; 27(11):1122-8. PubMed ID: 16958054
[TBL] [Abstract][Full Text] [Related]
19. The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis.
Gao LB; Pan XM; Sun H; Wang X; Rao L; Li LJ; Liang WB; Lv ML; Yang WZ; Zhang L
J Exp Clin Cancer Res; 2010 Aug; 29(1):117. PubMed ID: 20799949
[TBL] [Abstract][Full Text] [Related]
20. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.
Stredrick DL; Garcia-Closas M; Pineda MA; Bhatti P; Alexander BH; Doody MM; Lissowska J; Peplonska B; Brinton LA; Chanock SJ; Struewing JP; Sigurdson AJ
Hum Mutat; 2006 Jun; 27(6):538-44. PubMed ID: 16652348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
